Literature DB >> 21885113

Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells.

Adarsha Koirala1, Rasha S Makkia, Mark J Cooper, Muna I Naash.   

Abstract

Previously, we demonstrated that CK30PEG10k-compacted DNA nanoparticles (NPs) efficiently target photoreceptor cells and improve visual function in a retinitis pigmentosa model. Here, we test the ability of these NPs in driving transgene expression in the retinal pigment epithelium (RPE), using an RPE-specific reporter vector (VMD2-eGFP). NPs, uncompacted plasmid, or saline were subretinally delivered to adult BALB/c mice. NP-based expression was specific to RPE cells and caused no deleterious effects on retinal structure and function. eGFP expression levels in NP-injected eyes peaked at post-injection day 2 (PI-2), stabilized at levels ~3-fold higher than in naked DNA-injected eyes, and remained elevated at the latest time-point examined (PI-30). Unlike naked DNA, which only transfected cells at the site of injection, NPs were able to transfect cells throughout the RPE. Subretinal injections of rhodamine labeled NPs and naked DNA showed comparable initial uptake into RPE cells. However, at PI-7 and -30 days significantly more fluorescence was detected inside the RPE of NP-injected eyes compared to naked DNA, suggesting NPs are stable inside the cell which could possibly lead to higher and sustained expression. Overall, our results demonstrate that NPs can efficiently deliver genes to the RPE and hold great potential for the treatment of RPE-associated diseases. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21885113      PMCID: PMC3321842          DOI: 10.1016/j.biomaterials.2011.08.062

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  46 in total

Review 1.  Immune responses to adeno-associated virus and its recombinant vectors.

Authors:  J Y Sun; V Anand-Jawa; S Chatterjee; K K Wong
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

2.  Expression and localization of bestrophin during normal mouse development.

Authors:  Benjamin Bakall; Lihua Y Marmorstein; George Hoppe; Neal S Peachey; Claes Wadelius; Alan D Marmorstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-08       Impact factor: 4.799

3.  Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.

Authors:  Michael W Konstan; Pamela B Davis; Jeffrey S Wagener; Kathleen A Hilliard; Robert C Stern; Laura J H Milgram; Tomasz H Kowalczyk; Susannah L Hyatt; Tamara L Fink; Christopher R Gedeon; Sharon M Oette; Jennifer M Payne; Osman Muhammad; Assem G Ziady; Robert C Moen; Mark J Cooper
Journal:  Hum Gene Ther       Date:  2004-12       Impact factor: 5.695

4.  Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo.

Authors:  Assem-Galal Ziady; Christopher R Gedeon; Timothy Miller; William Quan; Jennifer M Payne; Susannah L Hyatt; Tamara L Fink; Osman Muhammad; Sharon Oette; Tomasz Kowalczyk; Murali K Pasumarthy; Robert C Moen; Mark J Cooper; Pamela B Davis
Journal:  Mol Ther       Date:  2003-12       Impact factor: 11.454

5.  Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung.

Authors:  Assem-Galal Ziady; Christopher R Gedeon; Osman Muhammad; Virginia Stillwell; Sharon M Oette; Tamara L Fink; Will Quan; Tomasz H Kowalczyk; Susannah L Hyatt; Jennifer Payne; Angela Peischl; J E Seng; Robert C Moen; Mark J Cooper; Pamela B Davis
Journal:  Mol Ther       Date:  2003-12       Impact factor: 11.454

6.  P2Y(2) receptor agonist INS37217 enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.

Authors:  May Nour; Alexander B Quiambao; Ward M Peterson; Muayyad R Al-Ubaidi; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-10       Impact factor: 4.799

7.  Subretinal perfluorocarbon liquids. An experimental study.

Authors:  J M de Queiroz; J C Blanks; S A Ozler; D V Alfaro; P E Liggett
Journal:  Retina       Date:  1992       Impact factor: 4.256

8.  Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain.

Authors:  Carmen S Peden; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation.

Authors:  Noriko Esumi; Yuji Oshima; Yuanyuan Li; Peter A Campochiaro; Donald J Zack
Journal:  J Biol Chem       Date:  2004-02-24       Impact factor: 5.157

10.  Rat retinal pigment epithelial cells show specificity of phagocytosis in vitro.

Authors:  P L Mayerson; M O Hall
Journal:  J Cell Biol       Date:  1986-07       Impact factor: 10.539

View more
  18 in total

1.  Nanoparticles in the ocular drug delivery.

Authors:  Hong-Yan Zhou; Ji-Long Hao; Shuang Wang; Yu Zheng; Wen-Song Zhang
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

2.  Synthesis and characterization of glycol chitosan DNA nanoparticles for retinal gene delivery.

Authors:  Rajendra N Mitra; Zongchao Han; Miles Merwin; Muhammed Al Taai; Shannon M Conley; Muna I Naash
Journal:  ChemMedChem       Date:  2013-11-07       Impact factor: 3.466

Review 3.  Drug and gene delivery to the back of the eye: from bench to bedside.

Authors:  Cheryl L Rowe-Rendleman; Shelley A Durazo; Uday B Kompella; Kay D Rittenhouse; Adriana Di Polo; Alan L Weiner; Hans E Grossniklaus; Muna I Naash; Alfred S Lewin; Alan Horsager; Henry F Edelhauser
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-28       Impact factor: 4.799

Review 4.  A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium.

Authors:  Adarsha Koirala; Shannon M Conley; Muna I Naash
Journal:  Biomaterials       Date:  2013-06-22       Impact factor: 12.479

5.  Direct gene transfer with compacted DNA nanoparticles in retinal pigment epithelial cells: expression, repeat delivery and lack of toxicity.

Authors:  Zongchao Han; Adarsha Koirala; Rasha Makkia; Mark J Cooper; Muna I Naash
Journal:  Nanomedicine (Lond)       Date:  2012-02-23       Impact factor: 5.307

6.  S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA.

Authors:  Adarsha Koirala; Rasha S Makkia; Shannon M Conley; Mark J Cooper; Muna I Naash
Journal:  Hum Mol Genet       Date:  2013-01-18       Impact factor: 6.150

7.  Nanoparticle-mediated miR200-b delivery for the treatment of diabetic retinopathy.

Authors:  Rajendra Narayan Mitra; Chance A Nichols; Junjing Guo; Rasha Makkia; Mark J Cooper; Muna I Naash; Zongchao Han
Journal:  J Control Release       Date:  2016-06-11       Impact factor: 9.776

8.  Persistence of non-viral vector mediated RPE65 expression: case for viability as a gene transfer therapy for RPE-based diseases.

Authors:  Adarsha Koirala; Shannon M Conley; Rasha Makkia; Zhao Liu; Mark J Cooper; Janet R Sparrow; Muna I Naash
Journal:  J Control Release       Date:  2013-09-11       Impact factor: 9.776

9.  Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery.

Authors:  Zongchao Han; Shannon M Conley; Rasha Makkia; Junjing Guo; Mark J Cooper; Muna I Naash
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

Review 10.  Nanotechnology approaches for ocular drug delivery.

Authors:  Qingguo Xu; Siva P Kambhampati; Rangaramanujam M Kannan
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.